연구성과로 돌아가기
2020 연구자 정보 (23 / 997)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Li, Daner (Li, D) |
MacroGenics, Rockville, MD USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Lockhart, A. Craig (Lockhart, AC) |
Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea Washington Univ, Sch Med, St Louis, MO USA Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Marrone, Kristen A. (Marrone, KA) |
Johns Hopkins Univ, Baltimore, MD USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Ng, Matthew C. H. (Ng, MCH) |
Duke NUS Med Sch, Natl Canc Ctr, Singapore, Singapore |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Nordstrom, Jeffrey L. (Nordstrom, JL) |
MacroGenics, Rockville, MD USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Park, Haeseong (Park, H) |
Washington Univ, Sch Med, St Louis, MO USA |
AAL-7982-2021 Park, Haeseong |
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Park, Se Hoon (Park, SH) |
Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea |
GMX-1199-2022 Park, Se Hoon |
0000-0001-5084-9326 Park, Se Hoon |
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Rosales, Minori Koshiji (Rosales, MK) |
MacroGenics, Rockville, MD USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Song, Eun-Kee (Song, EK) |
Chonbuk Natl Univ, Sch Med, Jeonju, South Korea |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Sym, Sun Jin (Sym, SJ) |
Gachon Univ, Gil Med Ctr, Incheon, South Korea |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Uronis, Hope E. (Uronis, HE) |
Duke Univ, Med Ctr, Durham, NC USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Wigginton, Jon (Wigginton, J) |
MacroGenics, Rockville, MD USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Yen, Jennifer (Yen, J) |
Guardant Hlth Inc, Redwood City, CA USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Yun, Jae Won (Yun, JW) |
Vet Hlth Serv Med Ctr, Vet Med Res Inst, Seoul 05368, South Korea Sungkyunkwan Univ, Dept Lab Med & Genet, Samsung Med Ctr, Sch Med, Seoul 06355, South Korea Korea Ctr Dis Control & Prevent, Div Infect Dis Control, Osong, South Korea |
AAT-4892-2020 AAF-7135-2019 Yun, Jae Yun, Jaewon |
|
[JCR상위 1.9] Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease The Practice Guideline for Vaccinating Korean Patients With Autoimmune Inflammatory Rheumatic Disease |
SCIE ESCI |
1.9 |
BIOCHEMISTRY & MOLECULAR BIOLOGY;CELL BIOLOGY INFECTIOUS DISEASES RHEUMATOLOGY |
ykchoi@knu.ac.kr;kpark@knu.ac.kr; heejinmd@korea.ac.kr;shinseok@chonnam.ac.kr; |
||
|
Cho, Yongjoon (Cho, Y) |
Ulsan Natl Inst Sci & Technol UNIST, Low Dimens Carbon Mat Ctr, Sch Energy & Chem Engn, Perovtron Res Ctr,Dept Energy Engn, Ulsan 44919, South Korea |
JQV-4650-2023 Cho, Yongjoon |
0000-0002-1199-0180 Cho, Yongjoon |
[JCR상위 2.1] Stable perovskite solar cells with efficiency exceeding 24.8% and 0.3-V voltage loss | SCIE | 2.1 | MULTIDISCIPLINARY SCIENCES | skkwak@unist.ac.kr;kimds@kier.re.kr;yang@unist.ac.kr; |
페이지 이동: